Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin and systemic inflammation in common variable immunodeficiency
2013-000883-27Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifaximin in common variable immunodeficiency (CVID) (2 arms), sponsored by Oslo University Hospital. Started Jun 2013; status: completed.
02
Drugs
rifaximin
03
Conditions
common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on 2013-000883-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000883-27.